Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy
Authors:
Open Access
- 1 December 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (48) , e8746
Abstract
Immunosuppressed patients with solid tumor malignancies (STMs) are particularly vulnerable to herpes zoster (HZ). This study estimated the incidence of HZ and evaluated healthcare resource utilization and costs for persons with STM receiving chemotherapy with and without incident HZ. We conducted a retrospective claims study of adults with STM receiving chemotherapy between January 1, 2010 and June 30, 2014. Patients were followed from their first chemotherapy date through development of HZ, health plan disenrollment, the study end date, or 24 months. HZ incidence was calculated and stratified by patient characteristics. Adjusted HZ incidence was estimated using Poisson regression. Healthcare resource utilization and costs were compared between patients with HZ (cases) and propensity score–matched controls without HZ during a variable follow-up period. Adjusted healthcare costs were estimated using Lin regression to control for informative censoring. Of 155,480 patients with STM receiving chemotherapy, 3100 (2.0%) developed HZ, yielding an adjusted HZ incidence rate of 13.8/1000 person-years (PY). HZ cases (n = 3004) had significantly higher healthcare resource utilization than matched controls (n = 15,020). Adjusted annual costs were $48,077 for cases vs $41,645 for matched controls, corresponding to a differential cost of $6432 annually. After adjustment for potential confounders, patients with STM receiving chemotherapy had an HZ incidence of 13.8/1000 PY; those who developed HZ used more healthcare resources and incurred higher costs than those who did not. These findings suggest that HZ prevention by vaccination could improve outcomes and reduce costs in this population.Keywords
This publication has 30 references indexed in Scilit:
- Chronic Medical Conditions as Risk Factors for Herpes ZosterMayo Clinic Proceedings, 2012
- Comparing Shingles Incidence and Complication Rates From Medical Record Review and Administrative Database Estimates: How Close Are They?American Journal of Epidemiology, 2011
- The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective studyCanadian Medical Association Journal, 2010
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- Incremental 1-Year Medical Resource Utilization and Costs for Patients with Herpes Zoster from a Set of US Health PlansPharmacoEconomics, 2009
- Herpes Zoster Risk Factors in a National Cohort of Veterans with Rheumatoid ArthritisClinical Infectious Diseases, 2009
- Vaccination against Herpes Zoster and Postherpetic NeuralgiaThe Journal of Infectious Diseases, 2008
- A critical appraisal of propensity‐score matching in the medical literature between 1996 and 2003Statistics in Medicine, 2007
- Herpes Infections in Breast Cancer Patients Treated with Adjuvant ChemotherapyOncology, 2006
- The Analysis of Categorical Data from Complex Sample Surveys: Chi-Squared Tests for Goodness of Fit and Independence in Two-Way TablesJournal of the American Statistical Association, 1981